Get the Stockscreener App
2.96
3.14%
0.09
After Hours:
2.95
-0.010
-0.34%
Processa Pharmaceuticals Inc stock is traded at $2.96, with a volume of 67,232.
It is up +3.14% in the last 24 hours and up +0.34% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
See More
Previous Close:
$2.87
Open:
$2.8
24h Volume:
67,232
Relative Volume:
1.20
Market Cap:
$7.87M
Revenue:
-
Net Income/Loss:
$-13.56M
P/E Ratio:
-0.3043
EPS:
-9.7281
Net Cash Flow:
$-12.24M
1W Performance:
-1.99%
1M Performance:
+0.34%
6M Performance:
-71.11%
1Y Performance:
-56.16%
1-Day Range:
$2.76
$2.99
1-Week Range:
$2.72
$3.135
52-Week Range:
$1.76
$19.63
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.96 | 7.63M | 0 | -13.56M | -12.24M | -9.7281 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Institution Moves: Is Processa Pharmaceuticals Inc impacted by rising rates2026 Price Targets & Verified Stock Trade Ideas - baoquankhu1.vn
Market Recap: What are the risks of holding Processa Pharmaceuticals IncMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Nasdaq Moves: Will Processa Pharmaceuticals Inc benefit from current market trendsPortfolio Profit Report & Safe Entry Point Alerts - baoquankhu1.vn
Weekly Recap: What is the implied volatility of Processa Pharmaceuticals Inc2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Market Outlook: Is Processa Pharmaceuticals Inc forming higher highs and higher lows2026 Performance Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Whale Trades: Is Processa Pharmaceuticals Inc impacted by rising ratesGDP Growth & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Heatwurx (NASDAQ:PCSA) versus Aquestive Therapeutics (NASDAQ:AQST) Critical Review - Defense World
Insider Buying: James Neal Acquires Shares of Processa Pharmaceu - GuruFocus
Processa Pharmaceuticals Insiders Increase Stock Holdings - Intellectia AI
Director Neal James R adds Processa (PCSA) shares in open trade - Stock Titan
Processa Pharma chief business officer Lin buys $4063 in PCSA By Investing.com - Investing.com India
Insider Buying: Russell Skibsted Acquires Shares of Processa Pha - GuruFocus
Russell Skibsted, CFO, buys Processa Pharma (PCSA) shares worth $5,891 - Investing.com UK
Russell Skibsted, CFO, buys Processa Pharma (PCSA) shares worth $5,891 By Investing.com - za.investing.com
Young David, processa pharma pres, buys PCSA shares worth $4588 - Investing.com
Processa Pharma director Pannu buys $5,252 in PCSA stock - Investing.com UK
Processa Pharma director Pannu buys $5,252 in PCSA stock By Investing.com - Investing.com Australia
Young David, processa pharma pres, buys PCSA shares worth $4588 By Investing.com - Investing.com Canada
Ng George K, Processa Pharma CEO, buys PCSA stock worth $5414 - Investing.com Canada
Baluch Khoso buys Processa Pharmaceuticals (PCSA) shares worth $5751 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (PCSA) R&D head adds 1,810 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (NASDAQ: PCSA) CFO buys 2,324 company shares - Stock Titan
Director Geraldine Pannu buys 2,072 Processa (PCSA) shares in market - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Baluch Khoso buys Processa Pharmaceuticals (PCSA) shares worth $5751 - Investing.com
Processa Pharmaceuticals (PCSA) officer adds 1,603-share open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) CAO buys 1,854 shares in open trade - Stock Titan
Processa (NASDAQ: PCSA) CDO buys 2,107 shares in open-market trade - Stock Titan
Director adds 2,269 Processa (PCSA) shares at $2.535 each - Stock Titan
Processa Pharmaceuticals, Inc.Common Stock (NQ: PCSA - The Chronicle-Journal
Weekly Earnings: Should I hold or sell Processa Pharmaceuticals Inc now2026 Volume & Verified Chart Pattern Trade Signals - baoquankhu1.vn
PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
Aug PreEarnings: What is Processa Pharmaceuticals Incs valuation compared to sector2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
PCSA PE Ratio & Valuation, Is PCSA Overvalued - Intellectia AI
Trading Recap: Does Processa Pharmaceuticals Inc have a sustainable dividend2026 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
Earnings Recap: Does Processa Pharmaceuticals Inc have strong fundamentalsRate Hike & Weekly Consistent Profit Watchlists - baoquankhu1.vn
If You Invested $1,000 in Processa Pharmaceuticals Inc (PCSA) - Stock Titan
Processa Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings - marketscreener.com
Aug Macro: Can Processa Pharmaceuticals Inc maintain sales growthMarket Growth Summary & Daily Price Action Insights - baoquankhu1.vn
Processa Pharmaceuticals Inc: Fundamental Analysis and Financial Ratings - marketscreener.com
Analyst Calls: What are the risks of holding Processa Pharmaceuticals Inc2026 Institutional & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Processa Pharmaceuticals 2025 Annual Report: Next Generation Cancer Therapies, Regulatory Strategy, Pipeline, and Intellectual Property Overview - Minichart
Processa Pharmaceuticals 2025 10-K: $0 revenue, $(10.36) EPS on $(13.56)M net loss - TradingView
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
[10-K] Processa Pharmaceuticals, I... - Stock Titan
Processa Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Processa Pharmaceuticals Inc expected to post a loss of $1.50 a shareEarnings Preview - tradingview.com
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Gardner News
Growth Recap: Whats Processa Pharmaceuticals Incs historical return2026 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):